children with congenital heart disease (CHD). This study estimated the cost-effectiveness of palivizumab prophylaxis versus … prophylaxis results in more QALYs than no prophylaxis in children with CHD. Palivizumab prophylaxis was shown to be a cost … later years, was constructed to evaluate the benefits and costs associated with palivizumab versus no prophylaxis among …

risk. The study assesses the cost-effectiveness of palivizumab versus no prophylaxis in infants at high risk of … infants at high risk of severe RSV infection who receive either prophylaxis with palivizumab or no prophylaxis. The main …: Prophylaxis with palivizumab compared with no prophylaxis is associated with the following ICERs; £33,216 for infants with …

Palivizumab is cost-effective compared to no prophylaxis in the United Kingdom in many of the subgroups considered …, showing that palivizumab would be a cost-effective use of National Health Service resources. </AbstractSection> Copyright …